Results 21 to 30 of about 18,252,794 (250)

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events [PDF]

, 2012
An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in ...
Christopher J Cates, Lasserson, TJ, Toby J Lasserson, Cates, CJ   +3 more
core   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Christopher J Cates, Lasserson, TJ, Toby J Lasserson, Cates, CJ   +3 more
core   +1 more source

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events [PDF]

, 2009
Epidemiological evidence has suggested a link between beta(2)-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta(2)-agonists are safe ...
Christopher J Cates, Jaeschke, R, Lasserson, TJ, Roman Jaeschke, Toby J Lasserson, Cates, CJ   +5 more
core   +1 more source

Treatment-related adverse events (TRAEs) (n = 12).

, 2023
Treatment-related adverse events (TRAEs) (n = 12).
Naoya Maekawa (575840), Satoru Konnai (469838), Ryohei Kinoshita (5226458), Kazuhiko Ohashi (469839), Yasuhiko Suzuki (378), Tomohiro Okagawa (575842), Sangho Kim (737402), Madoka Yokokawa (17094762), Yumiko Kagawa (575844), Tatsuya Deguchi (14510336), Yurika Tachibana (675437), Yukinari Kato (2825561), Satoshi Takagi (448831), Hiroshi Ohta (9656), Keiichi Yamamoto (17279), Hiroto Takeuchi (8959853), Kenji Hosoya (485640), Shiro Murata (575845), Ryo Owaki (17094759), Satoshi Yamamoto (316085)   +19 more
core   +1 more source

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors

Zhongliu Fangzhi Yanjiu, 2020
Immune checkpoint inhibitors(ICIs) has revolutionized the treatment of cancer. However, with the rapid application of CPIs, the immune-related adverse events (irAE) have attracted more and more attention.
ZHANG Xue, LI Dake
doaj   +1 more source

Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy. [PDF]

, 2014
Few data describe antiretroviral treatment (ART)-related adverse events when treatment is initiated at CD4 cell counts more than 350 cells/μl.
Chadwick, D, Gompels, Mark, Leen, Clifford, Fisher, Martin, Walsh, J, Hill, T, Hill, Teresa, Chadwick, David, Jose, Sophie, Fidler, S, Sabin, Caroline, UK CHIC Steering Committee, Walsh, John, Nelson, M, Sabin, C, Hay, Phillip, Johnson, M, Fidler, Sarah, Post, Frank, Gilson, Richard, Fisher, M, ?, ?, Jose, S, Johnson, Margaret, Quinn, Killian, Post, F, Gilson, R, Quinn, K, Hay, P, Leen, C, Gompels, M, Nelson, Mark   +31 more
core   +1 more source

Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2019
Background: Comprehensive evidence comparing treatment-related adverse events (trAEs) among PD-1/PD-L1 inhibitors is unavailable.Methods: A systematic review and network meta-analysis (NMA) was conducted.
Ya-fang Huang, Wen-jie Xie, Hai-yu Fan, Juan Du   +3 more
doaj   +1 more source

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Background: Anti-PD-(L)1 antibody monotherapy or in combination with VEGF(R) blockade has been applied widely for cancer treatment. Whether combination therapy increases irAEs still remains controversial.Methods: A systematic review and meta-analysis ...
Qiyu Tang, Dawei Wu, Huiyao Huang, Hong Fang, Ying Wu, Funan Liu, Ning Li   +6 more
doaj   +1 more source

Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events [PDF]

, 2014
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival.
Per M. Hellström, Groves, Richard, Michael Kreuter, Toby M. Maher, Maher, Toby M, Dewint, P. (Pieter), Sarafidis, A. (Alexandre), Vancheri, C. (Carlo), Egan, Jim JJ, Bendstrup, Elisabeth, Maher, T.M. (Toby), Bendstrup, E. (Elisabeth), Sarafidis, Alexandre, Egan, Jim J J, Vancheri, Carlo, Jim J. J. Egan, Costabel, Ulrich, Ferguson, James, Vincent Cottin, Nordlind, K. (Klas), Cottin, V. (Vincent), Hellström, Per M, Maher, Toby M., Carlo Vancheri, Richard Groves, Groves, R. (Richard), Costabel, U., Klas Nordlind, Dewint, Pieter, Nordlind, Klas, Cottin, Vincent, Ulrich Costabel, Ferguson, J.J. (James), Hellström, A.-L., Alexandre Sarafidis, Pieter Dewint, Egan, Jim J. J., Elisabeth Bendstrup, Kreuter, M. (Michael), Maria Molina-Molina, Molina-Molina, M. (Maria), James Ferguson, Kreuter, Michael, Egan, J.J.J. (Jim J.), Molina-Molina, Maria, Hellström, Per M., Hellström, Per M.,   +46 more
core   +1 more source

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors

Journal of Immunology Research, 2020
Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs).
Yan Xiao, Lin Zeng, Qinglin Shen, Zhiyong Zhou, Zhifang Mao, Qin Wang, Xiquan Zhang, Yingliang Li, Weirong Yao   +8 more
doaj   +1 more source